Zoonoses

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19

Retrieved on: 
Monday, July 12, 2021
Infectious diseases, Biotechnology, Health, Medical specialties, Branches of biology, Medicine, COVID-19, Occupational safety and health, Public health, Zoonoses, Antibody, Neutralizing antibody, Vaccine, COVID-19 testing, Catherine Blish

A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individuals immune response to the SARS-CoV-2 virus.

Key Points: 
  • A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individuals immune response to the SARS-CoV-2 virus.
  • We believe that as more people become vaccinated or exposed to the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics adds that next level of precision, delivering more detailed information of the strength of immune response against the virus.
  • This multi-multiplex approach to capturing the full spectrum of biomarkers associated with SARS-CoV-2 delivers a highly detailed snapshot of an individuals immune response in a single test cycle.
  • Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.

nference and Mayo Clinic Study Confirms Link Between Anemia and Rehospitalization After COVID-19 Infection Clearance

Retrieved on: 
Monday, July 12, 2021
Coronaviridae, Sarbecovirus, Zoonoses, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome, deCODE genetics

Authors of the study, " Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance ," found that pre-COVID-19 anemia is the strongest clinical signature of long-term COVID-19 phenotypes, and can appear weeks or months after a COVID-19 infection has been cleared from a patient's immune system.

Key Points: 
  • Authors of the study, " Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance ," found that pre-COVID-19 anemia is the strongest clinical signature of long-term COVID-19 phenotypes, and can appear weeks or months after a COVID-19 infection has been cleared from a patient's immune system.
  • By analyzing lab test results for patients rehospitalized after a COVID-19 infection, nference and Mayo Clinic researchers found that patients rehospitalized as a result of long-term COVID-19 symptoms are more likely to have experienced anemia before their diagnosis and during the time they were infected with COVID-19.
  • "This is an excellent demonstration of how nference triangulates various data sets to decode the natural history of diseases," said Venky Soundararajan, PhD, co-founder and chief scientific officer of nference.
  • Through its powerful augmented intelligence software nferX, nference is transforming health care by making biomedical knowledge computable.

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Retrieved on: 
Monday, July 12, 2021
COVID-19, Occupational safety and health, Public health, Zoonoses, Health, Articles, Clinical research

The data will be presented as an ePoster at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place online from 9-12 July 2021.

Key Points: 
  • The data will be presented as an ePoster at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place online from 9-12 July 2021.
  • Stanislas Veillet, President and CEO of Biophytis, said: These preclinical data are further evidence of the potential of Sarconeos (BIO101) to be an effective treatment for patients with COVID-19.
  • We are continuing our COVA Phase 2-3 study with Sarconeos (BIO101) in patients infected with COVID-19 and are looking forward to results of the second interim analysis in Q3 2021.
  • These forward-looking statements include statements regarding Biophytis anticipated timing for its various Sarconeos (BIO101) clinical trials and expectations regarding commercialization.

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Virology, Medicine, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Spike protein, COVID-19 vaccines, CIGA Healthcare, Abingdon Health

Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.

Key Points: 
  • Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • "The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho's leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used," said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics.
  • "Ortho's quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2."
  • The VITROS COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein, and a Total test that targets the nucleocapsid protein.

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Virology, Medicine, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Spike protein, COVID-19 vaccines, CIGA Healthcare, Abingdon Health

Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.

Key Points: 
  • Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • "The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho's leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used," said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics.
  • "Ortho's quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2."
  • The VITROS COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein, and a Total test that targets the nucleocapsid protein.

Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021

Retrieved on: 
Friday, July 9, 2021
Medicine, Clinical medicine, Branches of biology, Biomarkers, COVID-19, Occupational safety and health, Public health, Zoonoses, Systemic inflammation

SeptiCyte RAPID host immune response assay uses peripheral blood gene expression biomarkers to provide a probability of sepsis in patients presenting with clinical signs of systemic inflammation.

Key Points: 
  • SeptiCyte RAPID host immune response assay uses peripheral blood gene expression biomarkers to provide a probability of sepsis in patients presenting with clinical signs of systemic inflammation.
  • Immunexpress evaluated the performance of SeptiCyte RAPID using patient samples from COVID-19 positive cases as part of a retrospective cohort, collected by collaborators at Hospital del Mar, Barcelona, Spain.
  • Diagnostic performance demonstrated that SeptiCyte RAPID discriminated critical/severe COVID-19 cases from moderate/mild cases.
  • Additionally, SeptiCyte RAPID outperformed a commonly used clinical lab test for COVID-19 patient management, IL-6, with a p-value of 0.05.

Coronavirus Diagnostics Markets, 2026, By Type of Test (Molecular v/s Serology), By User (Multiple v/s Single), & Full Test Time - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021
Infectious diseases, Biotechnology, Health, Medical devices, COVID-19, Occupational safety and health, Public health, Zoonoses, Articles, Health, Medical tests

The Global Coronavirus Diagnostics Market was valued at USD73,538.02 million in 2020 and is expected to reach USD15579.56 million by 2026.

Key Points: 
  • The Global Coronavirus Diagnostics Market was valued at USD73,538.02 million in 2020 and is expected to reach USD15579.56 million by 2026.
  • The Global Coronavirus Diagnostics Market is driven by surging incidences of this disease across different parts of the globe.
  • The market is segmented based on type of test, user, full test time, end-user, company and region.
  • Based on type of test, the market can be bifurcated into molecular and serological tests.

Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Variants of SARS-CoV-2, Zoonoses, COVID-19, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus 2

Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.
  • The Delta variant is becoming the fastest moving, most dominant COVID-19 strain globally; on June 24th Therma Bright and its partners announced and initiated the Delta variant study.
  • The study focused on ensuring the Company's AcuVid COVID-19 Rapid Antigen Saliva Test would successfully perform and easily detect the ever-growing list of mutations from the original Wuhan SARS-CoV-2 Novel Coronavirus.
  • Sources: Delta variant news coverage as becoming the dominant COVID-19 variant in US, UK, Europe, India and Africa

Qatar Foundation: Arab Participation in Global Genomic Study Could Lead to New Therapies for COVID Patients

Retrieved on: 
Thursday, July 8, 2021
Public health, COVID-19, Occupational safety and health, Zoonoses, Genome-wide association study, Health, Branches of biology

The findings could help provide targets for future therapies and illustrate the power of genetic studies in learning more about infectious disease.

Key Points: 
  • The findings could help provide targets for future therapies and illustrate the power of genetic studies in learning more about infectious disease.
  • And these results come from one of the largest genome-wide association studies ever performed, which includes nearly 50,000 COVID-19 patients and two million uninfected controls.
  • QGP became the first and only member from the Arab world to contribute to this global effort, called the COVID-19 Host Genomics Initiative .
  • QF is also creating a multidisciplinary innovation hub in Qatar, where homegrown researchers are working to address local and global challenges.

Qatar Foundation: Arab Participation in Global Genomic Study Could Lead to New Therapies for COVID Patients

Retrieved on: 
Thursday, July 8, 2021
Public health, COVID-19, Occupational safety and health, Zoonoses, Genome-wide association study, Health, Branches of biology

The findings could help provide targets for future therapies and illustrate the power of genetic studies in learning more about infectious disease.

Key Points: 
  • The findings could help provide targets for future therapies and illustrate the power of genetic studies in learning more about infectious disease.
  • And these results come from one of the largest genome-wide association studies ever performed, which includes nearly 50,000 COVID-19 patients and two million uninfected controls.
  • QGP became the first and only member from the Arab world to contribute to this global effort, called the COVID-19 Host Genomics Initiative .
  • QF is also creating a multidisciplinary innovation hub in Qatar, where homegrown researchers are working to address local and global challenges.